207 related articles for article (PubMed ID: 28321893)
21. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Potter DM
Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
[TBL] [Abstract][Full Text] [Related]
22. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
23. An optimization algorithm for designing phase I cancer clinical trials.
Jiang H; Liu Y; Su Z
Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
[TBL] [Abstract][Full Text] [Related]
24. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
25. An approach to meta-analysis of dose-finding studies.
Zohar S; Katsahian S; O'Quigley J
Stat Med; 2011 Jul; 30(17):2109-16. PubMed ID: 21344473
[TBL] [Abstract][Full Text] [Related]
26. A Bayesian dose finding design for dual endpoint phase I trials.
Loke YC; Tan SB; Cai Y; Machin D
Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
[TBL] [Abstract][Full Text] [Related]
27. A two-dimensional biased coin design for dual-agent dose-finding trials.
Sun Z; Braun TM
Clin Trials; 2015 Dec; 12(6):596-607. PubMed ID: 26163309
[TBL] [Abstract][Full Text] [Related]
28. R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials.
Guo W; Ji Y; Li D
J Biopharm Stat; 2019; 29(3):411-424. PubMed ID: 30744484
[TBL] [Abstract][Full Text] [Related]
29. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
Wages NA; Conaway MR
Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
[TBL] [Abstract][Full Text] [Related]
30. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
31. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
32. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
Doussau A; ThiƩbaut R; Paoletti X
Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
[TBL] [Abstract][Full Text] [Related]
33. Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.
Huang B; Bycott P; Talukder E
J Biopharm Stat; 2017; 27(1):44-55. PubMed ID: 26882496
[TBL] [Abstract][Full Text] [Related]
34. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
35. An extension of the continual reassessment method using decision theory.
Leung DH; Wang YG
Stat Med; 2002 Jan; 21(1):51-63. PubMed ID: 11782050
[TBL] [Abstract][Full Text] [Related]
36. Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.
Shimomura A; Kondo S; Kobayashi N; Iwasa S; Kitano S; Tamura K; Fujiwara Y; Yamamoto N
Int J Clin Oncol; 2017 Aug; 22(4):780-785. PubMed ID: 28293794
[TBL] [Abstract][Full Text] [Related]
37. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.
Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
Stat Med; 2011 Jul; 30(17):2070-80. PubMed ID: 21344472
[TBL] [Abstract][Full Text] [Related]
38. Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group.
Chen Z; Krailo MD; Sun J; Azen SP;
Contemp Clin Trials; 2009 Mar; 30(2):123-8. PubMed ID: 19000782
[TBL] [Abstract][Full Text] [Related]
39. Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity.
Fernandes LL; Taylor JM; Murray S
J Biopharm Stat; 2016; 26(3):475-98. PubMed ID: 26098782
[TBL] [Abstract][Full Text] [Related]
40. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]